University of Minnesota
Investigating Chronic Inflammation in People with HIV on Antiretroviral Therapy
Abstract
dc:description.abstractAntiretroviral therapy (ART) has transformed human immunodeficiency virus (HIV) infection from a fatal illness into a chronic, manageable condition. However, despite ART, people with HIV (PWH) continue to experience greater morbidity and mortality than people without HIV (PWoH), in part because of an elevated risk of inflammation-mediated comorbidities such as cardiovascular disease and cancer. This excess risk is thought to stem from chronically elevated inflammation in PWH that, although attenuated by ART, is never fully resolved. Chronic inflammation in PWH on ART is believed to come from numerous sources, though the relative contribution of each to comorbidity and mortality risk remains poorly understood and likely varies substantially between individuals. These sources include microbial translocation from a disrupted gut microbiome and intestinal epithelial barrier, residual production of HIV gene products (viral RNA and protein) in latently infected cells, coinfections (e.g., cytomegalovirus), and lifestyle factors (e.g., smoking, drug use). In the absence of a widely available cure, resolving these sources of inflammation and preventing the comorbidities they drive is critical to improving long-term outcomes for the approximately 40.9 million PWH worldwide, 32.1 million of whom had access to ART as of 2024. Chapter one provides a detailed review of HIV pathogenesis, HIV-associated disruptions of the gut mucosa, and the impact of unresolved chronic inflammation in PWH on ART. Chapter two presents a multi-omic study of PWH on ART from two cohorts, in Mexico and the United States, integrating the gut microbiome, plasma metabolome, and plasma proteome to characterize geographic differences between PWH on ART and to identify biomarkers distinguishing those at high versus low risk of serious non-AIDS events. Chapter three investigates interactions between the gut microbiota and several mechanisms that could directly influence inflammation, including HIV latency reversal, antiretroviral (ARV) metabolism, and ARV-mediated modulation of the gut microbiome. Chapter four is a high-dimensional targeted metabolomics study of plasma from PWoH, virally suppressed PWH, and viremic PWH, aimed at defining the global impact of HIV infection on the plasma metabolome and identification of metabolic disruptions in PWH with viral suppression. Collectively, these results highlight distinct microbial, metabolic, and inflammatory biomarkers that distinguish PWH on ART with high-risk versus low-risk of serious, often inflammation-driven, comorbidities, reveal possible microbial mechanisms and interventions that could modulate inflammation in these individuals, and uncover novel lipid disruptions that persist despite viral suppression. Together, they point to multiple candidate mechanisms driving chronic inflammation in PWH on ART and to corresponding interventions that warrant future investigation to mitigate that inflammation and improve long-term health outcomes, which is the goal of my thesis studies.
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Basting, Christopher
Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Dc Identifier Citation
- Basting, Christopher. (2026). Investigating Chronic Inflammation in People with HIV on Antiretroviral Therapy. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/283095.